Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

Barchart · 1d ago

LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.